Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-04-19
2011-04-19
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387100, C536S023400, C435S069700
Reexamination Certificate
active
07928193
ABSTRACT:
The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.
REFERENCES:
patent: 2003/0073149 (2003-04-01), Archer et al.
patent: 2005/0019751 (2005-01-01), Cortese et al.
patent: WO 03/040726 (2003-05-01), None
Flint et al., “Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81,” Journal of Virology, vol. 73 No. 8, pp. 6235-6244 (Aug. 1999).
Meuleman et al., “Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo,” Hepatology, vol. 48 No. 6, pp. 1761-1768 (Dec. 2008).
Rduikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences, USA, vol. 79 No. 6, pp. 1979-1983 (Mar. 1982).
Webster et al., “Development of novel treatments for hepatitis C ,” The Lancet, col. 9 No. 2, pp. 108-117 (Feb. 2009).
Acton, S. et al. “Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor”, Science, 1996, vol. 271, pp. 518-520.
Agnello, V. et al. “Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor”, PNAS, 1999, vol. 96, pp. 12766-12771.
Azzazy, H. et al. “Phage display technology: clinical applications and recent innovations”, Clinical Biochemistry, 2002, vol. 35, pp. 425-445.
Bartosch, B. et al. “Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor”, The Journal of Biological Chemistry, 2003, vol. 278, pp. 41624-41630.
Berger, M. et al. “Therapeutic Applications of Monoclonal Antibodies”, The American Journal of the Medical Sciences, 2002, vol. 324, pp. 14-30.
Boel, E. “Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments”, Journal of Immunological Methods, 2000, vol. 239, pp. 153-166.
De Francesco, R. et al. “Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase”, Antiviral Research, 2003, vol. 58, pp. 1-16.
Krieger, M. “Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems”, The Journal of Clinical Investigation, 2001, vol. 108, pp. 793-797.
Liang, M. et al. “Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments”, Journal of Immunological Methods, 2001, vol. 247, pp. 119-130.
Patel, A. et al. “Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding”, Journal of General Virology, 2000, vol. 81, pp. 2873-2883.
Persic, L. et al. “An integrated vector system from the eukaryotic expression of antibodies or their fragments after selection from phage display libraries”, Gene, 1997, vol. 187, pp. 9-18.
Piero, P. et al. “Binding of Hepatitis C Virus to CD81”, Science, 1998 vol. 282, pp. 938-941.
Scarselli, E. et al. “The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus”, The EMBO Journal, 2002, vol. 21, pp. 5017-5025.
Temel, R. et al. “Scavenger receptor calss B, type 1 (SR-BI) is the major route for the delivery of high density lipoprotein cholesterol to the steriodogenic pathway in cultured mouse adrenocortical cells”, Proc. Natl. Acad. Sci., 1997, vol. 94, p. 13600-13605.
Urban, S. et al. “Scavenger Receptor BI Transfers Major Lipoprotein-associated Phospholipids into the Cells”, The Journal of Biological Chemistry, 2000, vol. 275, pp. 33409-33415.
Walker, M. et al. “Hepatitis C virus therapies: current treatments, targets and future perspectives”, Antiviral Chemistry & Chemotherapy, 2003, vol. 14, pp. 1-21.
Yoo, E. et al. “Myeloma expression systems”, Journal of Immunological Methods, 2002, vol. 261, pp. 1-20.
Patent Abstracts of Japan, “Monoclonal Antibody and Method for Producing the Same”, vol. 2003, No. 12, (JP 2004 331633, Nov. 25, 2004).
Chowdhury et al., Engineering scFvs for Improved Stability, p. 237-254 in Recombinant Antibodies for Cancer Therapy Methods and Protocols, (Eds. Weschof and Krauss) Humana PRess, Totowa, New Jersey 2003.
E.g., O'Brien, et al., Humanization of Monoclonal Antibodies by CDR Grafting, p. 81-100, FromMethodsin Molecular Biology vol. 207: Recombinant antibodies for Cancer Therapy: Methods and Protocols (Eds Welschof and Krauss) Humana Press, Totowa, New Jersey 2003.
Cortese Riccardo
Luzzago Alessandra
Nicosia Alfredo
Vitelli Alessandra
Heber Sheldon O.
Horning Michelle
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
Lucas Zachariah
Wenk Melissa B.
LandOfFree
Antigen binding proteins directed against scavenger receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen binding proteins directed against scavenger receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen binding proteins directed against scavenger receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705697